Annual EBITDA
-$111.76 M
-$2.29 M-2.10%
31 December 2023
Summary:
Tango Therapeutics annual earnings before interest, taxes, depreciation & amortization is currently -$111.76 million, with the most recent change of -$2.29 million (-2.10%) on 31 December 2023. During the last 3 years, it has fallen by -$60.28 million (-117.08%). TNGX annual EBITDA is now -117.08% below its all-time high of -$51.48 million, reached on 31 December 2020.TNGX EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly EBITDA
-$32.26 M
-$3.34 M-11.54%
30 September 2024
Summary:
Tango Therapeutics quarterly earnings before interest, taxes, depreciation & amortization is currently -$32.26 million, with the most recent change of -$3.34 million (-11.54%) on 30 September 2024. Over the past year, it has dropped by -$7.24 million (-28.96%). TNGX quarterly EBITDA is now -642.54% below its all-time high of -$4.34 million, reached on 30 June 2021.TNGX Quarterly EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TTM EBITDA
-$137.20 M
-$7.24 M-5.57%
30 September 2024
Summary:
Tango Therapeutics TTM earnings before interest, taxes, depreciation & amortization is currently -$137.20 million, with the most recent change of -$7.24 million (-5.57%) on 30 September 2024. Over the past year, it has dropped by -$29.84 million (-27.80%). TNGX TTM EBITDA is now -412.87% below its all-time high of -$26.75 million, reached on 30 September 2020.TNGX TTM EBITDA Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
TNGX EBITDA Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly | TTMTTM |
|---|---|---|---|
| 1 y1 year | -2.1% | -29.0% | -27.8% |
| 3 y3 years | -117.1% | -66.8% | -209.6% |
| 5 y5 years | - | - | - |
TNGX EBITDA High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | TTM vs highTTM vs high | TTM vs lowTTM vs low | |
|---|---|---|---|---|---|---|---|
| 3 y | 3 years | -117.1% | at low | -66.8% | +22.5% | -209.6% | at low |
| 5 y | 5 years | -117.1% | at low | -642.5% | +22.5% | -412.9% | at low |
| alltime | all time | -117.1% | at low | -642.5% | +22.5% | -412.9% | at low |
Tango Therapeutics EBITDA History
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2024 | - | -$32.26 M(+11.5%) | -$137.20 M(+5.6%) |
| June 2024 | - | -$28.92 M(-30.5%) | -$129.96 M(+5.1%) |
| Mar 2024 | - | -$41.63 M(+21.0%) | -$123.68 M(+10.7%) |
| Dec 2023 | -$111.76 M(+2.1%) | -$34.40 M(+37.5%) | -$111.76 M(+4.1%) |
| Sept 2023 | - | -$25.01 M(+10.5%) | -$107.36 M(-4.0%) |
| June 2023 | - | -$22.64 M(-23.8%) | -$111.85 M(-2.0%) |
| Mar 2023 | - | -$29.70 M(-1.0%) | -$114.10 M(+4.2%) |
| Dec 2022 | -$109.46 M | -$30.00 M(+1.7%) | -$109.46 M(+8.2%) |
| Date | Annual | Quarterly | TTM |
|---|---|---|---|
| Sept 2022 | - | -$29.51 M(+18.5%) | -$101.19 M(+11.2%) |
| June 2022 | - | -$24.89 M(-0.7%) | -$91.03 M(+29.1%) |
| Mar 2022 | - | -$25.07 M(+15.4%) | -$70.49 M(+23.0%) |
| Dec 2021 | -$57.29 M(+11.3%) | -$21.73 M(+12.3%) | -$57.29 M(+29.3%) |
| Sept 2021 | - | -$19.34 M(+345.3%) | -$44.31 M(-14.3%) |
| June 2021 | - | -$4.34 M(-63.4%) | -$51.72 M(+9.2%) |
| Mar 2021 | - | -$11.88 M(+35.8%) | -$47.38 M(+33.5%) |
| Dec 2020 | -$51.48 M | -$8.75 M(-67.3%) | -$35.50 M(+32.7%) |
| Sept 2020 | - | -$26.75 M | -$26.75 M |
FAQ
- What is Tango Therapeutics annual earnings before interest, taxes, depreciation & amortization?
- What is the all time high annual EBITDA for Tango Therapeutics?
- What is Tango Therapeutics annual EBITDA year-on-year change?
- What is Tango Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
- What is the all time high quarterly EBITDA for Tango Therapeutics?
- What is Tango Therapeutics quarterly EBITDA year-on-year change?
- What is Tango Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
- What is the all time high TTM EBITDA for Tango Therapeutics?
- What is Tango Therapeutics TTM EBITDA year-on-year change?
What is Tango Therapeutics annual earnings before interest, taxes, depreciation & amortization?
The current annual EBITDA of TNGX is -$111.76 M
What is the all time high annual EBITDA for Tango Therapeutics?
Tango Therapeutics all-time high annual earnings before interest, taxes, depreciation & amortization is -$51.48 M
What is Tango Therapeutics annual EBITDA year-on-year change?
Over the past year, TNGX annual earnings before interest, taxes, depreciation & amortization has changed by -$2.29 M (-2.10%)
What is Tango Therapeutics quarterly earnings before interest, taxes, depreciation & amortization?
The current quarterly EBITDA of TNGX is -$32.26 M
What is the all time high quarterly EBITDA for Tango Therapeutics?
Tango Therapeutics all-time high quarterly earnings before interest, taxes, depreciation & amortization is -$4.34 M
What is Tango Therapeutics quarterly EBITDA year-on-year change?
Over the past year, TNGX quarterly earnings before interest, taxes, depreciation & amortization has changed by -$7.24 M (-28.96%)
What is Tango Therapeutics TTM earnings before interest, taxes, depreciation & amortization?
The current TTM EBITDA of TNGX is -$137.20 M
What is the all time high TTM EBITDA for Tango Therapeutics?
Tango Therapeutics all-time high TTM earnings before interest, taxes, depreciation & amortization is -$26.75 M
What is Tango Therapeutics TTM EBITDA year-on-year change?
Over the past year, TNGX TTM earnings before interest, taxes, depreciation & amortization has changed by -$29.84 M (-27.80%)